What the Nasdaq determination letter means for Moolec Science’s future on the exchange

Moolec Science SA (NASDAQ: MLEC), a molecular-farming company developing plant-based food ingredients using animal protein genes, has confirmed that it received a formal determination letter from the Nasdaq Stock Market LLC on November 14, 2025. The letter informs the company that it is no longer in compliance with the minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2), following a sustained period where its ordinary shares closed below the mandatory threshold of US$1.00 for 30 consecutive business days.

What complicates the situation further is Nasdaq’s decision not to grant Moolec Science the usual 180-day automatic compliance period. This shortens the company’s window to regain listing compliance and raises the possibility of delisting if corrective measures are not taken or fail to restore the required bid price. Moolec Science has appealed the determination and requested a hearing with Nasdaq’s Hearings Panel to seek a cure period and explore remedial actions, including a potential reverse stock split.

Until the appeal is heard and ruled on, trading of Moolec Science’s ordinary shares will continue uninterrupted on the Nasdaq Capital Market under the ticker symbol “MLEC.”

Why did Moolec Science become non-compliant with Nasdaq listing rules?

Under Nasdaq’s listing standards, a company listed on the Nasdaq Capital Market is required to maintain a minimum bid price of at least US$1.00. Moolec Science’s stock has traded below that threshold since early September 2025, failing to regain compliance for the minimum 10 consecutive trading days required to reset the bid-price clock.

The determination letter also noted that Moolec Science does not qualify for a second 180-day compliance window, which would have required the company to meet alternative criteria such as a minimum of US$5 million in stockholders’ equity. Failing to meet this secondary threshold has now accelerated the timeline for Moolec Science to act.

Nasdaq’s refusal to grant an automatic extension signals that the exchange is taking a more stringent view of listing deficiencies, particularly among micro-cap stocks with thin trading volumes and limited equity buffers.

What options does Moolec Science have to regain compliance?

Moolec Science has officially filed a request for a hearing before the Nasdaq Hearings Panel, which allows the company to maintain its listing status temporarily while the appeal process unfolds. The hearing is scheduled to take place on December 18, 2025.

The company is currently evaluating its options, with a reverse stock split being the most immediate and likely path to restoring the bid price above US$1.00. Moolec Science had already executed a 1-for-10 reverse split earlier in 2025, which successfully lifted its share price above the threshold at that time. However, that earlier compliance window was not sustained, as the share price slipped again in the second half of the year.

Nasdaq’s updated regulatory posture also means that a reverse split alone may not suffice unless Moolec Science simultaneously demonstrates compliance with all other listing standards, including minimum public float, number of shareholders, and governance requirements.

How is Moolec Science’s stock performing in light of the compliance issue?

As of November 22, 2025, Moolec Science’s stock was trading around US$0.45 per share, significantly below the compliance threshold. This follows weeks of sub-dollar closes that have weighed heavily on sentiment. The company’s market capitalization has also dipped, reflecting eroded investor confidence and reduced institutional participation.

Analysts who track biotech and food-technology companies note that prolonged periods of non-compliance tend to amplify downside risk, especially for micro-cap stocks that are already navigating commercial uncertainty. In Moolec Science’s case, the listing overhang is viewed as a structural distraction that could delay or complicate efforts to secure fresh funding or partnerships.

Market watchers believe that until the compliance issue is resolved, the stock may continue to experience depressed liquidity and muted trading volume.

What is the wider impact on Moolec Science’s molecular farming strategy?

Moolec Science positions itself at the frontier of molecular farming—a niche area within the alternative protein and food-tech ecosystem. The company is working on developing high-value food ingredients by genetically engineering plants like soybean, safflower, and pea to express animal protein traits.

While the technology has drawn scientific interest and early-stage commercial attention, its path to scale and profitability remains complex. The delisting risk now compounds those execution challenges, as it may create hurdles in attracting strategic investors or entering commercial agreements that depend on visibility, governance, and public-market credibility.

Nasdaq listing status is often considered a baseline indicator of financial robustness. If Moolec Science fails to retain its listing, it could face a downgrade in perception, weakening its position in a competitive segment already dominated by larger players with more mature commercialization roadmaps.

What can investors expect in the coming weeks?

Investors will be closely watching the outcome of the Nasdaq Hearings Panel meeting scheduled for December 18. A favorable ruling could grant Moolec Science up to 180 days to regain compliance, provided it implements a viable plan—most likely a reverse split—and maintains compliance with other listing rules.

In addition to the technical listing risk, investors will also track other key signals such as announcements on new funding rounds, partnerships, product development milestones, and regulatory progress for Moolec Science’s protein-expressing crops.

Stock volume, insider buying, and analyst coverage are also likely to serve as indicators of confidence in the company’s ability to navigate the compliance challenge. However, if Moolec Science fails to convince the panel or execute on its plan, a delisting could trigger further downside, reduce investor reach, and even jeopardize its access to capital markets.

What is the expert view on Moolec Science’s outlook?

Industry analysts covering alternative protein and agri-biotech sectors believe Moolec Science’s compliance setback is serious but not insurmountable. The fact that the company has already gone through one successful reverse split earlier this year demonstrates its operational readiness to act quickly.

However, the broader concern is whether the business can generate enough commercial traction to offset regulatory and market pressures. Investors are likely to demand clearer visibility into Moolec Science’s monetization model and strategic partnerships, particularly after the current listing overhang is resolved.

In the short term, the compliance issue is likely to dominate headlines. But in the longer term, the company’s ability to validate its molecular farming platform, secure commercial agreements, and differentiate itself in a crowded food-tech market will determine whether it can rebuild investor trust and deliver on its growth ambitions.

How should investors interpret Moolec Science’s current crossroads and what comes next for the stock?

Moolec Science’s receipt of a Nasdaq determination letter marks a pivotal moment for the molecular-farming innovator. While the appeal process has bought the company more time, the risk of delisting is real if it fails to execute a convincing turnaround strategy. Investors are urged to monitor not only the bid price recovery but also the broader indicators of business momentum.

If Moolec Science regains compliance and stabilizes its operations, it could emerge stronger and more focused on delivering molecular farming at scale. But failure to meet Nasdaq’s requirements may signal deeper structural issues that will be harder to overcome. For now, all eyes are on the December 18 hearing—and what comes next.

What are the key takeaways from Moolec Science’s Nasdaq determination letter?

• Moolec Science SA received a formal determination letter from Nasdaq on November 14, 2025, citing non-compliance with the minimum bid-price requirement under Listing Rule 5550(a)(2).

• The company failed to maintain a closing bid price of at least US$1.00 for 30 consecutive business days and did not meet the US$5 million minimum equity requirement to qualify for an additional 180-day cure period.

• Nasdaq declined to grant the standard automatic extension, placing Moolec on an accelerated timeline to regain compliance or face potential delisting.

• Moolec Science has appealed the determination and requested a hearing with the Nasdaq Hearings Panel, currently scheduled for December 18, 2025.

• The company is considering a reverse stock split as a key part of its compliance strategy. This would not be the first time it uses this tool, having executed a 1-for-10 reverse split earlier in 2025.

• Moolec’s stock price remains below US$0.50 as of late November 2025, reflecting muted investor sentiment and heightened delisting concerns.

• Listing uncertainty adds another layer of pressure on Moolec’s broader molecular farming strategy, which involves engineering crops to express animal protein traits for the alternative protein market.

• Even if the company regains bid-price compliance, it must also demonstrate continued adherence to other listing standards, such as public float and governance metrics.

• Analysts expect the outcome of the December 18 hearing and the company’s ability to execute a compliance plan swiftly to determine whether Moolec maintains its Nasdaq listing.

• While Moolec’s core business operations remain unaffected for now, the listing issue may affect investor perception, institutional flows, and long-term strategic credibility in the food-tech sector.